ALK and non-small cell lung carcinoma: The retrospective studies indicated that the median age of diagnosis for ALK+ NSCLC was approximately 60 years (Auliac et al., 2017; Lim et al., 2017), and these older patients have comorbidities and polypharmacy (Decoster and Schallier, 2019), which may increase TKI-mediated toxicities during long-term treatment.